Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Signature block only; no material agreement terms disclosed in the provided text.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Signature block only; no material agreement terms disclosed in the provided text
- CEO Sean Bohen signed the filing on May 1, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.